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Abstract 
This study widens the transferability of cost–utility results from the SCOT trial showing that administering 3 
months of adjuvant, oxaliplatin-based chemotherapy is cost-effective and cost saving compared to 6 months 
from the perspective of all countries recruited to SCOT. The impact on healthcare budgets if the findings are 
implemented as predicted will amount to savings of at least US$150 million over 5 years. 
Background: The Short Course Oncology Treatment (SCOT) trial demonstrated non-infer ior it y, less toxicit y, and cost- 
effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal 
cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial 
findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, 
and the United Kingdom. Patients and Methods: Individual cost–utility analyses were performed from the perspective 
of each country. Resource, quality of life, and survival estimates from the SCOT trial ( N = 6065) were used. Probabilistic 
sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost–utility analyses, 
the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5- 
year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity 
analysis addressed uncertainty within the budget impact analysis. Results: Three months of treatment were cost saving 
and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit 
per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the 
base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million 
across all countries. Conclusion: This study has widened the transferability of results from the SCOT trial, showing 
that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could 
fully justify the investment in conducting the SCOT trial. 
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Adjuvant chemotherapy offers a survival benefit for patients
with colorectal cancer (CRC), but at the expense of toxic-
ity. 1-5 When oxaliplatin-based treatment is used, peripheral nerve
damage is a particular concern. 6 The Short Course Oncol-
ogy Treatment (SCOT) trial 7 demonstrated that 3 months of
adjuvant, fluoropyrimidine–oxaliplatin chemotherapy was non-
inferior compared with 6 months of treatment and demonstrated
significantly less toxicity. In particular, the percentage of patients
experiencing ≥grade 2 peripheral neuropathy was less than half in
the 3-month arm versus the 6-month arm. 7 
Clinical effectiveness of CRC treatments is the key considera-
tion for clinicians and policymakers. However, due to the high
disease burden and substantial cost of treating CRC, 8 assessing
the cost-effectiveness of novel treatments is important and often a
requirement of health technology assessment authorities globally. 9 
In addition, even if a new treatment is cost-effective, this does not
illustrate the economic implications of using the new treatment
approach in practice. Several health technology assessment authori-
ties now also require a budget impact analysis (BIA) to estimate the
monetary impact of implementing a new strategy and displacing the
current standard of care within their healthcare service. 10 
Multinational trials, such as SCOT, have several advantages.
Patient recruitment is expedited, patients from several countries are
given the opportunity to participate in research, and the generaliz-
ability of clinical results is widened. 11 , 12 The transferability of cost-
effectiveness estimates among countries, however, is not straightfor-
ward. This is partly due to heterogeneity in unit costs, the varying
structures of healthcare systems, and the various thresholds used by
decision makers to assess whether a treatment is considered good
value for money. 12-15 Nonetheless, if health economic data within a
trial have been collected from different locations, it is important that
attempts are made to provide value estimates for all participating
countries. 12 , 16 Three months of adjuvant, doublet chemotherapy
for CRC has previously been shown to be cost-effective compared
with 6 months from the perspective of the UK National Health and
Personal Social Services. 17 
The aim of this study was to estimate the value, and economic
implications of using a shorter duration of adjuvant treatment
for patients with CRC across all locations that recruited patients
to SCOT. The main objectives were to (1) evaluate the cost-
effectiveness of 3 versus 6 months of adjuvant, oxaliplatin-based
chemotherapy for patients with CRC from the perspective of the
healthcare systems in Australia, Denmark, New Zealand, Spain,
Sweden, and the UK; and (2) estimate the budget impact in these
countries if the SCOT trial findings were implemented. 
Methods 
First, demographic, disease, and treatment-related characteristics
for patients enrolled in SCOT from each country were assessed.
Non-adjusted, average (median) compliance with fluoropyrimidine
and oxaliplatin therapy was calculated specific to patients from each
country. 
An analysis of the cost-effectiveness of using shorter treatment
from the perspective of each individual country was performed,
followed by an evaluation of the likely budget implications ofintroducing shorter treatment in each location. The approach
used for each assessment is described in detail in Supplemen-
tal Table 1A (per CHEERS reporting guideline 18 ; see the online
version at doi:10.1016/j.clcc.2021.04.001) and Supplemental Table
3A (per BIA ISPOR guideline 10 ; see the online version at
doi:10.1016/j.clcc.2021.04.001). 
For both analyses, a healthcare system perspective was adopted,
and calculations were performed in US dollars (US$) unless other-
wise specified, with 2019 as the base year. Health-specific purchas-
ing power parity 19 was used to convert country-specific costs to US
dollars. The sources of chemotherapy medication costs are shown in
Table 2A (see the online version at doi:10.1016/j.clcc.2021.04.001).
For hospitalization unit costs, results from the World Health
Organization Choice project 20 were utilized to calculate the ratio
of between-country differences in inpatient and outpatient costs,
using the United Kingdom as the reference country. This ratio was
applied to the Scottish Information Services Division 2019 unit
costs relevant to hospitalization resource use collected within the
SCOT trial. 
Analysis of Cost-Effectiveness 
A 10-year within-trial time horizon was used, with extended
follow-up compared to the previous cost–utility analysis (CUA). 17 
Quality adjusted life-years (QALYs) were estimated using parti-
tioned survival analysis with Kaplan–Meier estimates of time on
treatment, disease-free survival after treatment, and recurrence,
weighted by health utilities, which were calculated by applying
country-specific preferences. 21 , 22-26 EQ-5D responses were available
for a subgroup of patients ( n = 1832); therefore, linear regression
analysis was used to adjust for health state (time on treatment,
disease-free survival, and recurrence), regimen received, disease risk,
age, gender, and ethnicity. For years 0 to 6, average costs for patients
in both arms of the trial, accrued over prespecified time intervals,
were adjusted for the probability that a patient in that arm of the
trial survived to the start of the time point using the Kaplan–Meier
estimator. For year 7, resource use data presented a considerable level
of missing information, and no data were available for years 8 to 10.
Therefore, a model estimated yearly costs after controlling for trial
arm, time from randomization, and the same covariates included in
the utility model. 
To estimate the cost-effectiveness of shorter treatment for each
country, six fully pooled, single-country costing analyses were
undertaken. 27 , 28 Outcomes and resource use from all countries
were pooled, and country-specific unit costs and utility scores were
applied to resource use and EQ-5D answers, respectively, for all
patients in the trial. No adjustment was made for clustering at the
country level within the survival analysis. A fully pooled, multi-
country costing analysis was also performed and used for subgroup
analyses. The multi-country approach pooled outcome and resource
use data but applied unit costs and utilities specific to the location
from which each individual patient was recruited. 
The incremental net monetary benefit (INMB) of using 3
months versus 6 months was calculated using a willingness to pay
(WTP)/QALY threshold of one gross domestic product per capita
for each country. 29 Both costs and outcomes after year 1 were
discounted at a rate of 3.5% per annum. Probabilistic sensitiv-Clinical Colorectal Cancer September 2021 237 
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Figure 1 Summary of Estimation of Eligible Population for Budget Impact Analysis and Parameters Used in a 




































238 ity analysis was undertaken to account for uncertainty regarding
costs, QALYs, and cost-effectiveness outcomes using bootstrapping
with 1000 iterations; the results are presented as confidence inter-
vals around point estimates. 17 Deterministic sensitivity analysis was
undertaken to explore the INMB for 3 months versus 6 months of
treatment over a range of WTP thresholds. 
Analysis of Budget Impact 
Figure 1 outlines the approach used for the BIA. The eligi-
ble population consisted of patients diagnosed with stage II or III
CRC who receive adjuvant oxaliplatin-based doublet chemotherapy.
The number of patients diagnosed with CRC in each country was
derived from the published literature, and an estimate of the propor-
tion of patients who receive adjuvant chemotherapy, and those who
receive doublet treatment specifically, was applied (see Supplemental
Table 4A in the online version at doi:10.1016/j.clcc.2021.04.001). 
Rather than assuming that all patients would receive shorter
treatment after the SCOT trial findings were disseminated, an
international clinician survey (April 2019) was used to estimate
practice change (see Supplemental Table 4A in the online version at
doi:10.1016/j.clcc.2021.04.001). 30 The survey estimates accountedClinical Colorectal Cancer September 2021 for differences in practice changes for patients under 70 years of age
versus 70 years and over. A cost calculator in Microsoft Excel 2016
was used to calculate the country-specific budget impact for a base-
case scenario over 5 years. Average undiscounted per-patient costs
for chemotherapy medication and hospitalization resource utiliza-
tion per annum for years 1 to 5 from each arm of the SCOT
trial specific to each country were used. Uncertainty regarding key
parameters ( Figure 1 ) in the BIA was addressed in a one-way sensi-
tivity analysis. In addition, a scenario analysis was performed to
exclude patients with rectal cancer and to look at the budget impact
relevant to patients with stage II CRC and stage II/III colon cancer
separately. 
Results 
Country-specific characteristics for SCOT trial patients ( N =
6055) are shown in Table 1 . Notable differences included the
fact that Australian clinicians preferred leucovorin calcium (folinic
acid), fluorouracil, and oxaliplatin (FOLFOX; 78%), whereas those
from Denmark, New Zealand, and the United Kingdom preferred
capecitabine and oxaliplatin (CAPOX). There was a relatively even
split of CAPOX versus FOLFOX use for patients from Sweden and
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Table 1 Differences in Patient, Disease, and Treatment Characteristics Among Patients Recruited From Different Countries in the 
SCOT Trial (N = 6065) 
Australia 
( n = 196, 
3.2) 
Denmark 
( n = 310, 
5.1) 
New Zealand 
( n = 16, 0.3) 
Spain 
( n = 233, 
3.8) 
Sweden 
( n = 82, 
1.4) 
United Kingdom 
( n = 5228, 86.2) 
Patient Characteristics 
Age (y) 
Mean (min/max) 64 (39/83) 64 (23/81) 65 (48/78) 63 (38/80) 63 (32/78) 63 (20/85) 
Median (IQR) 65 (58-71) 65 (59-70) 66 (61-71) 64 (57-69) 65 (59-69) 65 (58-70) 
Gender, n (%) 
Male 112 (57) 178 (57) 11 (69) 143 (61) 51 (62) 3177 (61) 
Female 84 (43) 132 (43) 5 (31) 90 (39) 31 (38) 2051 (39) 
Performance status, n (%) 
0 160 (82) 248 (80) 12 (75) 180 (77) 75 (91) 3642 (70) 
1 36 (18) 62 (20) 4 (25) 53 (23) 7 (9) 1586 (30) 
Disease Characteristics 
Extended risk stage, n (%) 
II 4 (2) 85 (27) 0 (0) 62 (27) 7 (9) 956 (18) 
Low III 117 (60) 129 (42) 8 (50) 99 (42) 34 (41) 2281 (44) 
High III 75 (38) 96 (31) 8 (50) 72 (31) 41 (50) 1991 (38) 
Treatment 
Drug regimen, n (%) 
FOLFOX 152 (78) 45 (15) 4 (25) 110 (47) 40 (49) 1620 (31) 
CAPOX 44 (22) 265 (85) 12 (75) 123 (53) 42 (51) 3608 (69) 
Treatment Compliance (%), Median (IQR) 
Fluoropyrimidine 
3 mo 97 (89-99) 94 (86-98) 91 (87-96) 97 (91-99) 93 (88-98) 94 (81-99) 
6 mo 90 (58-97) 79 (49-92) 79 (65-92) 92 (80-98) 85 (59-96) 82 (56-94) 
Oxaliplatin 
3 mo 97 (89-99) 87 (63-97) 99 (90-100) 98 (93-99) 95 (87-98) 95 (81-99) 
6 mo 70 (53-87) 43 (25-66) 78 (74-79) 85 (60-97) 62 (37-72) 70 (45-86) 


































Spain. No patients with stage II disease were recruited from New
Zealand, although the overall number from this country was small.
Unsurprisingly, treatment compliance was better for the 3-month
trial arm, and compliance with fluoropyrimidine exceeded that for
oxaliplatin across both arms and all countries. 
Costs 
The average undiscounted chemotherapy and hospitalization cost
per patient for each country of using 3 months versus 6 months
of treatment and differences in treatment durations are shown in
Figure 2 . Costs calculated using a multi-country approach aligned
closely with those from the United Kingdom because most patients
in the SCOT trial were from this location. 
Outcomes 
Supplemental Figure 2B (see the in the online version at
doi:10.1016/j.clcc.2021.04.001) shows the Kaplan–Meier survival
curves used for the purposes of this analysis. Using 10-year survival
data, restricted mean life expectancy (see Supplemental Table A6
in the online version at doi:10.1016/j.clcc.2021.04.001; not statis-
tically significant) was higher for patients in the 3-month versus6-month arm. Supplemental Figure 3B (see the in the online version
at doi:10.1016/j.clcc.2021.04.001) demonstrates the change in
quality-of-life estimates over time calculated using country-specific
utility weights. Overall, health-related quality-of-life estimates were
lowest for New Zealand and highest for Sweden. QALY gains for
the 3-month versus 6-month treatment strategy ranged from 0.11
for Sweden to 0.17 for New Zealand ( Table 2 ). 
Cost Utility, Sensitivity, and Subgroup Analyses 
Overall, 3 months of treatment was a dominant strategy
compared with 6 months across all locations. The INMB was
greater than US$8000, with over 99% probability that the 3-
month arm was cost-effective for all countries at a WTP thresh-
old of one gross domestic product per capita. Figure 3 demon-
strates the INMB across a range of WTP thresholds. Sweden had
one of the highest cost savings; therefore, at lower WTP it provided
the highest INMB. As the WTP for a QALY gain increased, the
INMB was highest from a New Zealand perspective because of the
highest QALY gain when New Zealand-specific EQ-5D weights
were applied to the calculation of utilities. The cost-effectiveness
acceptability curve and cost-effectiveness plane for each locationClinical Colorectal Cancer September 2021 239 
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Figure 2 Mean Undiscounted Costs Per Patient Per Arm and Differences Between Trial Arms for Each Country 
Using a Fully Pooled Costing Approach and a Multi-Country Perspective Using a Multi-Country Costing 
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240 are shown in Supplemental Figure 4B (see the online version
at doi:10.1016/j.clcc.2021.04.001). Subgroup analysis results are
provided in Supplemental Figure 5B (see the online version at
doi:10.1016/j.clcc.2021.04.001). There was most uncertainty in
cost-utility estimates for patients receiving FOLFOX. At a WTP
threshold of US$42,000, the probability of 3 months of FOLFOX
being cost-effective was 77% compared with 99% for CAPOX. 
Analysis of Budget Impact 
The healthcare system savings of implementation of SCOT trial
findings over 5 years ranged from US$3.6 million (New Zealand)
to over US$61.4 million (United Kingdom) ( Table 3 ; Table for
country-specific currency, see also Supplemental Table A7 in the
online version at doi:10.1016/j.clcc.2021.04.001). The combined
base-case budget impact was US$152 million. The impact for New
Zealand was lowest due to the smallest eligible population and cost
difference per patient. Although the eligible population in Spain wasClinical Colorectal Cancer September 2021 higher than in the United Kingdom, higher per-patient cost savings
from a UK perspective led to larger estimated budget savings. 
BIA Sensitivity Analysis 
In a one-way sensitivity analysis (see Supplemental Figure 6B in
the online version at doi:10.1016/j.clcc.2021.04.001), when it was
assumed that all patients with stage III CRC received 3 months
rather than 6 months of adjuvant doublet chemotherapy following
dissemination of SCOT trial findings, the overall potential budget
savings amounted to US$297 million. Removing patients with stage
II disease from the analysis ( Table 3 ; see Supplemental Figure 6B
in the online version at doi:10.1016/j.clcc.2021.04.001) had little
effect (total budget impact, US$145 million) because of the small
stage II CRC population deemed eligible to be affected by a practice
change in the base scenario. Excluding patients with rectal cancer in
a scenario analysis led to a decrease in the budget impact by less than
half (total impact of US$102 million). 
Catherine R. Hanna et al 







NMB Using a WTP Threshold of One 
GDP (Country-Specific) per Capita, 
US$ (95% CI) 
Probability of Being 
CE at WTP of 1 × GDP 
per Capita (%) 
Australia GDP for Australia: 53,000 
3 mo 37,289 (35,520-39,226) 6.28 (6.17-6.40) 295,494 (288,886-302,170) 99.6 
6 mo 42,830 (40,691-44,999) 6.13 (6.00-6.26) 282,158 (275,037-239,783) 0.4 
Incremental –5541 (–8383 to 2624) 0.14 (–0.01 to 0.30) 13,337 (4265-22,533) 3M dominates 
Denmark GDP for Denmark: 62,000 
3 mo 36,357 (34,639-38,242) 6.35 (6.25-6.47) 357,653 (350,583-365,053) 99.6 
6 mo 41,744 (39,660-43,856) 6.22 (6.10-6.34) 343,768 (335,926-352,194) 0.4 
Incremental –5386 (–8156 to 2544) 0.13 (–0.01 to 0.28) 13,884 (4011-24,119) 3M dominates 
New Zealand GDP for New Zealand: 42,000 
3 mo 27,133 (25,889-28,514) 5.80 (5.67-5.93) 216,261 (210,639-222,158) 99.6 
6 mo 31,264 (29,736-32,793) 5.63 (5.49-5.77) 204,983 (198,714-211,365) 0.4 
Incremental –4131 (–6148 to 2013) 0.17 (0.002-0.34) 11,278 (3886-19,311) 3M dominates 
Spain GDP for Spain: 31,000 
3 mo 28,443 (27,119-29,909) 6.44 (6.33-6.56) 171,245 (167,196-175,464) 99.8 
6 mo 32,583 (30,961-34,217) 6.29 (6.16-6.41) 162,273 (158,018-166,987) 0.2 
Incremental –4,140 (–6286 to 1893) 0.15 (–0.00 to 0.31) 8972 (3409-14,602) 3M dominates 
Sweden GDP for Sweden: 52,000 
3 mo 37,104 (35,244-39,079) 6.56 (6.46-6.65) 303,778 (298,231-309,245) 99.5 
6 mo 42,515 (40,353-44,770) 6.44 (6.34-6.54) 292,493 (286,508-298,774) 0.5 
Incremental –5411 (–8383 to 2418) 0.11 (–0.02 to 0.24) 11,285 (3557-18,942) 3M dominates 
United Kingdom GDP for United Kingdom: 40,000 
3 mo 31,629 (30,144-33, 269) 6.27 (6.16-6.39) 219,347 (214,184-224,628) 99.6 
6 mo 36,182 (34,368-38,023) 6.12 (5.99-6.25) 208,673 (203,051-214,704) 0.4 
Incremental –4553 (–6955 to 2056) 0.15 (–0.01 to 0.31) 10,674 (3683-17,928) 3M dominates 
Multi-country NICE threshold: £30,000 (US$42,000) 
3 mo 31,594 (30,092-33,227) 6.27 (6.16-6.39) 231,932 (226,577-237,410) 99.6 
6 mo 36,150 (34,333-38,008) 6.12 (6.00-6.25) 220,949 (215,104-227,210) 0.4 
Incremental –4557 (–6932 to 2097) 0.15 (–0.01 to 0.31) 10,983 (3684-18,664) 3M dominates 
Abbreviations: 3M = 3 months; CE = cost-effective; CI = confidence interval; GDP = gross domestic product; NICE = National Institute for Health and Clinical Excellence; NMB = net monetary 
benefit; QALYs = quality adjusted life-years; WTP = willingness to pay. 
Table 3 BIA Base Case and Scenario Analysis in Country-Specific Currency 
US$ 
Australia Denmark New Zealand Spain Sweden United Kingdom 
Base Scenario Budget Impact 
Chemotherapy medication costs over 5 y 2.0 0.5 0.3 1.8 0.8 1.9 
Treatment-related hospitalizations in (year 1 for 
each individual patient) over 5 y 
21.4 6.5 3.1 40.2 8.8 56.1 
Condition-related hospitalizations (years 2-5 for 
each individual patient) over 5 y 
1.3 0.4 0.2 2.4 0.6 3.4 
Total budget impact = medication cost + cost of 
treatment and condition-related hospitalizations 
24.7 7.4 3.6 44.4 10.2 61.4 
Scenario Analysis (Per Base Scenario) 
Colon cancer only 17.1 5.0 2.4 29.2 6.9 41.3 
Stage III only (CRC) 23.5 7.1 3.4 42.4 9.8 58.7 
Stage III only (colon cancer) 16.3 4.7 2.3 27.9 6.6 39.5 
Stage II only (colon cancer) 0.8 0.2 0.1 1.3 0.3 1.8 
All values for budget impact included in this table indicate cost savings. 
Abbreviation: CRC = colorectal cancer. 
Clinical Colorectal Cancer September 2021 241 
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Figure 3 Incremental NMB Over a Range of WTP Thresholds for Each Country (Fully Pooled, One-Country 
Costing Analysis) and Using a Fully Pooled, Multi-Country Costing Analysis. UK and Multi-Country 
























































Adjuvant, oxaliplatin-based chemotherapy for 3 months is cost-
effective and cost saving compared to 6 months from the perspec-
tive of all countries that recruited patients to the SCOT trial. Using
survival data with follow-up until 10 years, mean life expectancy
was better in the 3-month arm (not statistically significant), whereas
in the previous CUA (8-year follow-up) life expectancy was non-
significantly higher in the 6-month arm. 17 Also, although there was
a QALY gain from shorter treatment in the previous CUA, it was
higher in this study (only statistically significant for New Zealand),
driven both by increased life expectancy and quality-of-life improve-
ment. These results have updated the cost-effectiveness analysis from
a UK perspective by using the most recently available survival data
and have increased the relevance of the CUA to clinicians from
other countries. Specifically, clinicians and policymakers will now
have country-specific estimates of QALY gains and cost savings to
guide their decision making. 
Subgroup analysis revealed that the cost-effectiveness of using 3
months versus 6 months of treatment was less certain for patients
receiving FOLFOX, especially at higher WTP thresholds. This was
because of the small mean benefit in life expectancy from using
longer treatment with this regimen (not statistically significant).
There may be patient- or disease-specific factors that affect clinician
preference for using FOLFOX rather than CAPOX for an individ-
ual patient, such as the presence of an ileostomy, difficulty swallow-
ing tablets, or concerns regarding compliance with oral medica-
tion. In combination with updated clinical effectiveness results from
SCOT and the other International Duration Evaluation of Adjuvant
Chemotherapy (IDEA) collaboration trials, 31 , 32 clinicians can useClinical Colorectal Cancer September 2021 the information from this study when making decisions on treat-
ment duration for patients in whom FOLFOX is their regimen of
choice. This study has also provided cost-effectiveness estimates for
low- and high-risk stage III disease and stage II disease with high-risk
features. Such estimates provide additional information compared
with the previous CUA, which split risk stage using a binary division
between patients with high-risk stage III disease versus low-risk stage
III and stage II disease combined. 
Approximately 1.8 million people 33 are diagnosed with CRC per
annum globally, with the cost of managing this disease projected to
be over US$39 billion 34 ; around half of these patients 35 present with
stage II or III disease. Making savings relevant to this patient cohort
therefore has significant cost consequences for healthcare systems
globally. This study shows that implementing SCOT trial findings
in six high-income countries translates to savings of hundreds of
millions of dollars, and the total global impact is likely to be
several times this estimation. This study used a relatively conserva-
tive estimate of practice change, based on a large clinician survey
conducted in April 2019 and adjusted for the likely proportion
of patients actually receiving adjuvant chemotherapy after surgi-
cal resection and a reduced use of doublet chemotherapy versus
monotherapy in older patients. The findings from the BIA sensitiv-
ity analysis using a higher level of practice change may be useful to
country-specific decision makers if they know that the proportion
of patients receiving 3 months of doublet chemotherapy in their
location is higher than the average estimate used in this study. 
In addition to providing useful information to country-specific
decision makers, this study also provides an estimate of the longer
term consequences of conducting the SCOT trial. Specifically,

























































































the results demonstrate how the magnitude of healthcare system
savings compare to the project-specific funding invested by chari-
ties and research councils to conduct the SCOT trial (see the
funding section of Supplemental Table 3A in the online version
at doi:10.1016/j.clcc.2021.04.001). Although the charities and
research councils that invested in SCOT will not recoup these costs
directly, many cancer research funders are interested in knowing
that their investments are leading to societal impact, which includes
economic benefits for healthcare systems. 36-39 
This study has some important limitations. First, when using a
fully pooled approach, varying unit costs alone is likely to under-
estimate between-country differences compared with fully splitting
the analyses. 12 For the purposes of the BIA, an assumption was
made that the clinicians who reported that they prescribed 3 months
of doublet chemotherapy after SCOT used 6 months of doublet
chemotherapy before SCOT. There is most uncertainty surrounding
how this applies to patients with stage II disease, because improve-
ment in overall survival from adding oxaliplatin to fluoropyrimi-
dine has not been demonstrated for this patient group 40 , 41 ; for this
reason, clinicians may give fluoropyrimidine monotherapy in this
situation. This uncertainty was addressed by excluding patients with
stage II disease within the BIA scenario analysis. 
Also, despite being included in several international guidelines,
the use of doublet chemotherapy in the adjuvant setting for rectal
cancer is more controversial compared with its use for colon cancer,
with fewer randomized trials to support its use. The budget change
estimates for rectal cancer were therefore more uncertain compared
with those for colon cancer and the reason why patients with rectal
cancer were excluded within a sensitivity analysis. Finally, the BIA
assumed that the proportion of patients receiving FOLFOX versus
CAPOX before and after SCOT was the same as in the SCOT trial. 7
Given the higher uncertainty regarding the non-inferiority of using
3 months of FOLFOX, clinicians may switch to CAPOX. This is
most relevant to clinicians from Australia, who showed a preference
for FOLFOX within the SCOT trial. 
Conclusion 
This study has widened the transferability of cost–utility results
from the SCOT trial. We encourage this type of analysis alongside
multinational clinical trials to ensure that all countries that recruited
patients to the trial have results relevant to their decision makers.
This study has also estimated a 5-year healthcare budget impact of
implementing SCOT trial findings of over US$150 million across
six countries over 5 years. These savings could fully justify the invest-
ment in conducting the SCOT trial. 
Clinical Practice Points 
 What is already known? Administering 3 months of adjuvant
oxaliplatin-base chemotherapy is cost-effective compared with 6
months from a UK perspective. Prior to this study, it was not
clear if these results were transferrable to patients from other
countries or what the real-world cost savings of implementing
shorter treatment would be. 
 What are the new findings? Using updated survival data from the
SCOT trial, this study has demonstrated that shorter treatment
is still cost-effective compared with 6 months of chemotherapyfrom a UK perspective. Additional analyses have provided
cost-effectiveness estimates from the perspectives of the five
other countries that were also recruited to SCOT and have
shown that 3 months of chemotherapy can be both cost-effective
and offer cost savings across all locations and over a range of
willingness-to-pay thresholds. In this study, the cost savings of
implementing SCOT trial findings have been estimated using
country-specific medication and hospitalization unit costs and
total at least US$150 million over 5 years. 
 How might these findings impact clinical practice in the foresee-
able future? UK and international clinicians and policymakers will
now have contemporary and country-specific cost-effectiveness
estimates to supplement clinical efficacy results from SCOT when
making decisions. The budget impact results will be particularly
useful to clinicians involved in healthcare resource allocation and
those who are interested in understanding the wider impacts from
implementation of clinical trial findings. Specifically, the budget
impact results can be used by clinician trialists to advocate for
funding investment in future cancer trials. 
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